Regulatory Mechanisms and Promising Applications of Quorum Sensing-Inhibiting Agents in Control of Bacterial Biofilm Formation

1A biofilm is a large number of bacterial cell aggregates coated in an extracellular mucous comprised of a polysaccharide matrix, lipids, and proteins, which they secrete. Bacteria tend to form biofilms when exposed to external environmental pressure, such as extreme nutrient deficiency or excess, high osmotic pressure, low pH, oxidative stress, antibiotics and antimicrobial agents. It is a state of self-protection formed when bacteria grow on the surfaces of objects under natural conditions. Any bacteria in nature can form a biofilm under mature conditions, and more than 90% of bacteria live and grow primarily in the form of biofilms.

2Biofilms may irreversibly form on a wide variety of surfaces, including living tissues, industrial or potable water system piping, indwelling medical devices, and natural aquatic systems, and once it is formed, it cannot be removed by gentle rinsing. More than 60% of all bacterial infections are caused by biofilm formation, according to a public announcement from the National Institutes of Health (NIH). The formation of biofilms leads to not only common bacterial infections, such as infections of the urinary tract, catheters, children’s middle-ear, common dental plaque formation, and gingivitis, but also to hard-to-treat or relapsing infections and severe infections that cause serious morbidity and mortality.

3Currently, the use of antibiotics is still the major treatment for bacterial infectious diseases. However, biofilms, being a barrier that exists around bacterial cells, reduces the susceptibility of bacteria to antibiotics and causes persistent infections. It has been shown that bacteria in a biofilm increase their resistance against antibiotics by about 1000-fold. Thus, it is hard to control bacterial infections with conventional antibiotics due to the presence of biofilms. Therefore, it is urgent to find a strategy to inhibit the formation of biofilms to control these increasingly serious infections.

4At present, it is well known that bacteria forming a biofilm is under the control of the quorum sensing system (QS). The QS involves cell-to-cell communication among bacteria using small diffusible chemical signaling molecules called autoinducers (AIs). The signaling molecules accumulate in the surrounding environment with an increase of bacterial density. When the concentration of signaling molecules reaches a minimal threshold, they bind to receptor proteins, thereby activating the expression of genes associated with biofilm formation. QS inhibiting agents, including QS inhibitors (QSIs) and quorum quenching (QQ) enzymes, can cut off QS cell communication via a variety of mechanisms, consequently inhibiting the formation of biofilms. In addition, QS inhibiting agents can also increase bacterial sensitivity to antibiotics. Therefore, the use of QS inhibiting agents would be a promising approach to control bacterial infections.

5In this review, we summarize the mechanisms by which QS inhibiting agents regulate biofilm formation, some strategies for the discovery of new QS inhibiting agents, and the current applications of QS inhibiting agents in medical and industrial fields. We aim to provide a new perspective for exploring more effective antibiotic drugs through the use of QS inhibiting agents.

6Quorum sensing regulatory networks are not only very complicated but also vary among bacterial species. Therefore, the regulatory mechanisms of QS on biofilm formation cannot be described in general. However, based on the types of employed AIs, QS systems can be divided into several categories, namely, AHL system, AIP system (these two system known as AI-1 system previously), AI-2 system and AI-3 system.

7The AHL system exists in Gram-negative bacteria and the signaling molecules employed in this system are N-acyl homoserine lactones (AHLs). While, autoinducing peptides (AIPs) are employed in the AIP system and this system is found only in Gram-positive bacteria. Presently, there are a large number of studies on these two systems.

8However, there are only a few reports about AI-2 and AI-3 systems, although these two systems have been found to be present in both Gram-positive and Gram-negative bacterial species and to participate in interspecies signal exchange. AI-2 signaling molecules are a class of furanosyl borate diesters whose precursors are 4,5-dihydroxy-2,3-glutara dione (DPD). The AI-3 signaling molecules have recently been identified as pyrethroids. The mechanism of how the QS system regulates biofilm formation is described in detail below for Gram-negative and positive bacteria separately.

9The signaling molecule of the AHL system in Gram-negative bacteria is AHL. The AHL-mediated QS system was first found in Vibrio fischeri. In this bacterium, the AHL signal, N-(3-oxohexanoyl)-L-homoserine lactone (OHHL), is biosynthesized by AI synthase LuxI, and the resulting OHHL diffuses out of the bacterial cell. When the concentration of OHHL reaches a critical threshold with the increase of cell density, OHHL binds to LuxR, which is not only an OHHL receptor, but also a DNA-binding transcriptional activator, thereby activating the expression of genes associated with biofilm formation. Presently, it is well known that this regulatory process is a typical model for the regulation of biofilm formation by AHL systems in most Gram-negative bacteria.

10Take Pseudomonas aeruginosa for instance, which has two AI synthase genes, lasI and rhlI, which both share significant sequence homologies to luxI of V. fischeri. Their signals, N-(3-oxo-dodecanoyl)-l-homoserine lactone (OdDHL) and N-butyryl-l-homoserine lactone (BHL), are separately synthesized by LasI and RhlI. When they reach the concentration threshold, these two AHL signaling molecules bind to their receptors, LasR and RhlR, respectively, to activate the expression of regulatory genes related to biofilm formation and virulence. Among these two AHL systems, the rhl system is involved in regulating swarming motility that participates in the early stage of biofilm establishment, and the biosynthesis of virulence factors, such as rhamnolipid and pyocyanine. The las system controls genes encoding elastase, alkaline protease, endotoxin A and other genes related to biofilm formation.

11In addition, in P. aeruginosa, there are also two other types of AHLs-mediated systems, the pqs system and the iqs system. These two systems work in a way similar to the rhl and las systems, though their AIs, PQS (2-heptyl3-hydroxy-4-quinolone) and IQS (2-(2-hydroxyphenyl)-thiazole-4-carbaldehyde), are chemically different from AHLs. Additionally, the pqs system has been reported to be related to the synthesis of bacterial extracellular DNA, which is important for the formation of biofilms. In brief, the four AHL systems, las, rhl, iqs and pqs, cross-interact to form a complicated QS network that co-regulates biofilm formation by P. aeruginosa.

12The AHL system is also involved in the regulation of biofilm formation in Escherichia coli. However, different from the AHL system in P. aeruginosa, only the receptor gene sdiA homologous to luxR is found and the AHL synthase gene homologous to luxI is absent. Hence, it is speculated that the receptor SdiA may respond to the AHLs produced by other bacterial species to regulate biofilm-related gene expression. The finding that in the presence of exogenous AHLs, there is an increase of EPS production in E. coli and the attachment of bacterial cells confirms that bacteria can utilize the signaling molecules of other bacterial species for biofilm formation.

13Currently, AI-2 systems have been found to affect biofilm formation in several Gram-negative species, such as Helicobacter pylori, E. coli, V. parahemolyticus, P. aeruginosa and V. cholerae. However, at present, only the regulatory mechanisms of the AI-2 systems in E. coli and V. cholerae have been clarified. In E. coli, the AI-2 signaling molecule is transported into the cell by an ABC transporter protein when the extracellular concentration of the AI-2 signaling molecule reaches its threshold. The resulting signaling molecule is then phosphorylated by LsrK kinase followed by binding to the transcriptional regulator LsrR, thereby activating gene expression. In V. cholerae, the AI-2 signaling molecule is detected by the receptor complex LuxPQ. When the signaling molecule concentration reaches its threshold, the kinase activity of LuxQ is converted to phosphatase, which dephosphorylates downstream regulatory protein LuxO, resulting in the production of transcriptional regulatory protein HapR, thereby inhibiting the transcription of genes related to biofilm formation.

14AI-3 signaling molecules are currently known to be related to the formation of flagellum and adhesin in E. coli, but their regulatory mechanisms for biofilm formation remain unclear.

15In Gram-positive bacteria, the AIs of the AIP system are AIPs, and the regulation of biofilm formation by the AIPs-mediated QS system is also a typical pattern. Bacteria produce a small oligopeptide in their cells, and the oligopeptide is processed into a mature AIP through modification and then it is transported outside of the cells. When the concentration of AIP reaches its threshold, it binds to the extracellular segment of histidine kinase, a transmembrane receptor localized on the cell membrane, which leads to the activation of the kinase, followed by phosphorylation of downstream response regulatory factors, resulting in regulation of the expression of genes related to biofilm formation.

16For example, in Staphylococcus aureus, five genes, agrA, agrB, agrC, agrD and hld in the agr operon constitute the agr AIP system. The signaling AIP is converted from its precursor peptide AgrD, and AgrB, a transmembrane protein, is responsible for the conversion of AgrD to mature AIP and transportation of the resulting AIP outside of the cell. When the extracellular AIP concentration reaches its threshold, the AIP binds to an extracellular part of AgrC, an integral transmembrane protein functioning as a histidine kinase, resulting in the activation of the kinase. The activated AgrC in turn phosphorylates the downstream response regulator AgrA. Phosphorylated AgrA binds to the intergenic DNA between promoters P2 and P3, and thus activates promoter transcription. The agr system has been shown to play a major role in the dispersion phase, which is the last stage of biofilm formation. Agr mutants formed a thicker biofilm comparing with the wild type, but this increased biofilm thickness has been attributed to the inability of cells to detach from the mature biofilm, not to cell growth or death.

17Presently, there are several reports about the regulation of biofilm formation by the AI-2 system in Gram-positive bacteria. For example, a study has shown that the lack of luxS, which encodes AI-2 synthase, promotes the transcription of rbf, a positive regulatory factor for biofilm formation, and results in an increase of biofilm formation and higher levels of production of polysaccharide intercellular adhesion (PIA) in S. aureus. However, the opposite finding, that the absence of luxS decreases biofilm formation, was also found in Enterococcus faecalis and Streptococcus suis. Nevertheless, the AI-2 system is involved in the regulation of biofilm formation in Gram-positive bacteria, but its regulatory mechanism has not yet been fully characterized.

18In addition, there is still no report about the AI-3 system in regard to the control of biofilm formation in Gram-positive bacteria.

19In the past two decades, a number of effective QS inhibiting agents have been developed and successfully used to control the formation of bacterial biofilms. These QS inhibiting agents are mainly QS inhibitors (QSIs) and quorum quenching (QQ) enzymes. Although different types of QSIs or QQ enzymes interfere with different parts of the QS signaling pathway, the inhibitory mechanism can be divided into three categories based on their functional targets, i.e., targeted to AI signaling molecules, receptors and downstream signaling cascades (Figure 1). These three mechanisms are described in detail with examples as follows.

20The QS inhibiting agents that target the AI signaling molecules are mainly AHL-lactonases, oxidoreductases, antibodies, and some other molecular compounds (Table 1). These agents inhibit the QS system by inactivation of signaling molecule synthases, neutralization of AIPs with antibodies, modification or degradation of the signaling molecules, etc.

21Degradation or neutralization of QS signaling molecules by QQ enzymes are a direct and effective way to inhibit the QS system. In Gram-negative bacteria, AHLs can be degraded by two types of hydrolases, AHL-lactonase and AHL-acylase. An AHL-lactonase, encoded by aiiA of Bacillus spp and belonging to the metallo-β-lactamase superfamily, has been determined to effectively inhibit biofilm formation and attenuate virulence factors in several bacterial species. Another QQ enzyme, AHL-acylase, is not widespread in Gram-negative bacteria. However, the enzyme has been found to be present at least in P. aeruginosa, and it has been shown to degrade AHLs with side chains and hence enable the bacteria to modulate the QS system. Currently, there are few reports on the degradation of AIPs by QQ enzymes in Gram-positive bacteria. However, AIPs can be neutralized by antibodies and cause interruption of QS signaling. For example, an anti-AI monoclonal antibody can efficiently inhibit QS via neutralization of an AI peptide (AIP-4) that is produced by S. aureus.

22N-acyl homoserine lactones oxidoreductase, another class of QQ enzyme, has also been reported in Gram-negative bacteria, it modifies the AIs and thereby attenuates the specific binding of the AIs to the corresponding receptors, resulting in a decrease of biofilm formation. BpiB09 is a metagenome-derived NADP-dependent reductase and it has been found to be involved in inactivation of the QS signaling molecule OdDHL. Although the AHLs of P. aeruginosa are probably not the native substrate of BpiB09, the expression of the enzyme in P. aeruginosa results in poor biofilm formation, significantly reduced pyocyanin production and decreased motility. Another AHL oxidoreductase, Hod, a 2,4-dioxygenase, is capable of catalyzing the conversion of PQS to N-octanoylanthranilic acid and carbon monoxide. Exogenous supplementation of Hod protein into P. aeruginosa cultures reduces expression of the PQS biosynthetic enzyme PqsA and the PQS-regulated virulence factors. In short, these QQ enzymes can effectively inhibit bacterial biofilm formation.

23Inhibiting the biosynthesis of QS signaling molecules may be a more direct way to interrupt the QS system and inhibit biofilm formation. Some QS inhibitors have been found to inhibit the synthetic activities of AIs synthases. TofI is an AHL synthase identified in the Gram-negative bacterium Burkholderia gluma. The binding site of TofI can be occupied by an AHL analog and therefore disturb AHL synthesis. Another example is diketopiperazines that target CepI, an AHL synthase of B. cenocepacia, can interfere with the activity of signaling molecule synthases, rendering the bacteria unable to produce biofilms.

24The second mechanism of QS inhibiting agents is by targeting the receptors of the QS signaling molecules, thereby inactivating the receptor or competing for the receptor. In most cases, the ligand binding domains of receptors with the native AIs are highly conserved, which can be competitively or non-competitively bound by most AIs (Table 2). Two classes of QS inhibiting agents, flavonoids and furanones, have been found that can bind to receptors of a variety of pathogenic bacteria. A plant flavonoid, naringenin, competes with the physiological signaling molecule OdDHL by directly binding to the receptor LasR, resulting in inhibition of the production of the QS-regulated virulence factors, pyocyanin and elastase, etc., in P. aeruginosa. Also in P. aeruginosa, the receptor LasR can interact with sitagliptin, a drug used for the treatment of diabetes mellitus type 2, and a minor inhibitory concentration of sitagliptin significantly inhibits biofilm formation. In addition, flavonoids can non-competitively bind to the LasR LBD and prevent the protein from binding to DNA, causing repression of certain QS behaviors. Moreover, some QS inhibiting agents can bind to different receptors at the same time. For example, 3-benzene lactic acid (PLA), a QS inhibiting agent produced by Lactobacillus, antagonistically binds to the receptors RhlR and PqsR with a higher affinity than its cognate ligands BHL and PQS in P. aeruginosa.

25As another class of QS inhibiting agents, furanones, can compete with the native AIs to bind to, and subsequently block, the AHL receptors. They have been demonstrated to significantly decrease virulence factor production and biofilm formation in a range of bacterial species. In addition to competing with signaling molecules for receptors, some QS inhibiting agents, such as meta-bromo-thiolactone, can also directly inactivate the receptors to prevent virulence factors expression and biofilm formation.

26The third mechanism of inactivation of QS systems is blocking the signaling cascade by deactivating the downstream response regulators or other regulatory factors. For example, in the AIP system of S. aureus, downstream response regulator AgrA is phosphorylated and thereby activated, which is triggered by upstream signaling, and it binds to DNA sequences associated with promoters and upregulates the expression of relevant genes as described above. Inhibiting the response regulators can block the signaling cascade and prevent the formation of a bacterial biofilm (Table 3). Savarin, for example, is a small molecule identified as an S. aureus virulence inhibitor, which can specially target AgrA to disrupt agr operon-mediated QS, and hence inhibit biofilm formation.

27In addition to acting on the response regulator, the QS inhibiting agents can also act on other regulatory factors to block signaling cascades. For example, virstatin, a small molecule that acts to prevent the expression of cholerae virulence factors, can repress the expression of AnoR, which is a positive regulator of the LuxI-like synthase AnoI in Acinetobacter nosocomialis, leading to decreased synthesis of N-(3-hydroxy-dodecanoyl)-L-homoserine lactone (OH-dDHL), thus affecting the signaling cascade, and reducing biofilm formation and motility. Moreover, efflux pumps inhibitor PAβN reduces the extracellular accumulation of QS signaling molecules and significantly decreases the relative expression of the QS cascade (pqsA, pqsR, lasI, lasR, rhlI and rhlR) in P. aeruginosa clinical isolates, and this is followed by a reduction of bacterial virulence.

28In the past two decades, researchers have discovered plenty of QS inhibiting agents that can effectively inhibit biofilm formation in bacteria. The development of new QS inhibiting agents that can effectively replace antibiotics has been a hot topic in the antibacterial research field. With the increasing degree of bacterial resistance to antibiotics, it has become more urgent to develop new QS inhibiting agents that can effectively inhibit biofilm formation. Here, we will introduce four strategies for exploiting new QS inhibitors.

29Some QS inhibitors are usually structural analogs of AIs, which cause the inactivation of QS by competitively binding to the receptor. Therefore, the synthesis of derivatives of known QSIs that do not alter the core structure may be an effective strategy. Actually, researchers have used natural and chemically synthesized halogenated furanones to successfully synthesize furanone analogs bearing alkyl chains, vinyl bromide keys or aromatic rings, and these analogs can also inhibit biofilm formation. In addition, C-5 aromatic substituted furanones have been designed and synthesized based on 5-hydroxyl-3,4-halogenated-5H-furan-2-ones, and this compound shows remarkable inhibition of biofilm formation as well as inhibition of virulence factor production in P. aeruginosa. Moreover, a new class of brominated furanones that contained a bicyclic structure were designed and synthesized, and this class of molecules exhibited reduction in the toxicity to mammalian cells, but retained the inhibitory activity toward biofilm formation of bacteria.

30The use of quenching enzymes to interfere with QS is an attractive strategy to fight bacterial infections. Intentional modification of QQ enzymes by using protein engineering methods may obtain greater efficiency and stability of quenching enzymes. Thus, this could be an effective strategy for developing new QQ enzymes. MomL is a marine lactonase that can degrade various AHLs. Two MomL mutants, MomLI144V and MomLV149A, exhibit higher activities to block the production of virulence factors of Pectobacterium carotovorum subsp. carotovorum (Pcc). PvdQ is an acylase with effective QQ activity in P. aeruginosa, but it hardly hydrolyses short-chain AHLs. However, its variant PvdQLα 146W,Fβ 24Y has an altered substrate specificity, and it exhibits high hydrolysis activity toward shorter-chain AHLs such as C8-HSL.

31There are abundant biochemical resources in plants and microorganisms in nature. In recent years, a number of natural products have been found to have potential abilities of inhibition of QS signaling and biofilm formation with the extensive use of computer-aided programs like structure-based virtual screening (SB-VS) and molecular docking bioassays. Natural plant-derived compounds trans-cinnamaldehyde (CA) and salicylic acid (SA) can significantly inhibit the expression of QS-regulated genes involved in virulence, rhamnolipid and reduced biofilm formation in P. aeruginosa. Recently, a novel AHL acylase, MacQ, has been identified from a multidrug-resistant bacterium, Acidovorax sp. strain MR-S7, and it was able to degrade a wide variety of AHLs, ranging from C6 to C14 side chains with or without 3-oxo substitutions, thus interfering with the QS system in the bacterial pathogen.

32The search for QS inhibiting agents from the library of drugs approved for clinical applications may be a promising way to shorten the period of development of an anti-QS drug from discovery to clinical use, since long-term clinical trials are needed to ensure QS inhibiting agents are safe and reliable before they can be used to treat infectious diseases. A typical example of a new therapeutic use of an old drug is niclosamide, which is an FDA approved anti-helminthic drug. Niclosamide has been identified to strongly inhibit the QS response by targeting the las QS system, thereby reducing the expression of las regulon-controlled virulence factors and biofilm formation in P. aeruginosa. Another FDA approved drug that is used for the treatment of upper respiratory tract infections and for tracheobronchial infections caused by Gram-positive pathogens, clofoctol, has also been found to significantly reduce biofilm formation through inhibiting the pqs QS system in P. aeruginosa. In addition, albendazole, also an FDA approved clinical drug, has been found to have great potential to act as a QS inhibitor. It quenches the QS by interacting with the hydrophobic amino acid residues of the hydrophobic pocket of CviR and LasR receptors in P. aeruginosa. Antibiotics have also shown great potential as QS inhibiting agents. For exsample, aminoglycosides, a commonly used class of antibiotics, exhibit biofilm inhibition by targeting the QS regulatory protein LasR in P. aeruginosa.

33As a new type of antimicrobial agent, QS inhibiting agents have been applied in several fields, such as in medical treatments, food processing and water treatment.

34Currently, QS inhibiting agents are widely used in health-related fields. P. aeruginosa is a major cause of nosocomial infections, especially in the pulmonary infections associated with cystic fibrosis. This organism shows a remarkable capacity to resist antibiotics. Alternative drugs have proven useful against this multiresistant strain. The acylase PvdQ has been identified as an QS inhibiting agent that can irreversibly hydrolyze AHL signaling molecules and has great therapeutic efficacy against pulmonary infections in a mouse model.

35In addition, owing to biofilms being one of the important virulence factors of pathogenic bacteria, infections resulting from the formation of biofilms on medical devices remains a significant clinical problem. Therefore, a poly(ethylene glycol) (PEG) based multifunctional coating that allows for the covalent incorporation of the synthetic QS inhibitor 5-methylene-1-(prop-2-enoyl)-4-(2-fluorophenyl)-dihydropyrrol-2-one (DHP) in a surface can reduce biofilm formation, and the use of this coating can reduce bacterial colonization. Obviously, this provides a useful way to prevent device-related infections. Moreover, QS inhibiting agents can also be used as antibiotic accelerants for treating bacterial infections. Two cinnamic acid derivatives, 4-dimethylaminocinnamic acid (DCA) and 4-methoxycinnamic acid (MCA) as AHL inhibitors, were both found to not only markedly inhibit biofilm formation, but also to enhance the susceptibility of biofilms to tobramycin.

36In addition to great application prospects in the health-related fields, QS inhibiting agents can also be used in the food industry. Food safety has always been a major concern in the food industry. The formation of biofilms enhances the attachment of bacterial pathogen to the surface of food packaging bags or processing equipment, which increases post-processing contamination and risks to public health due to their persistence and resistance to cleaning and disinfection procedures. Thus, the extraction of QS inhibiting agents from foodborne materials to solve food contamination problems is a relatively effective approach. The essential oils that were extracted from Murraya koenigii were found to have strong QS inhibitory and anti-biofilm activities that can reduce cell attachment, metabolic activity and EPS production, and in addition, they could delay the decomposition of refrigerated milk caused by psychrophila PSPF19. Additional applications of QS inhibiting agents in the food industry are still being explored.

37At present, the application of quenching QS in water treatment has also been reported, and it shows great potential and commercial prospects. In wastewater treatment, membrane bioreactor (MBR) is an important technique that combines the activated sludge and membrane filtration processes. However, biofouling, which is mainly caused by the generation of a thickened biofilm layer resulting from bacterial gathering, is a primary problem during the use of MBR, which seriously affects the efficiency of wastewater treatment. QQ enzymes can be employed to prevent biofouling in MBR. For instance, immobilized a QQ enzyme (acylase) onto a nano-filtration membrane, and found the acylase-immobilized membrane prohibits the formation of the mushroom-shaped mature biofilm and prevents more than 90% of the initial flux after 38 h operation, while the un-immobilized raw membrane dropped to 60% accompanied by severe biofouling.

38There are studies showing that the use of QS inhibiting agents may also be an effective strategy to eradicate biofilm contamination in metalworking fluids (MWFs). Biofilm contamination is a critical problem in MWFs, which not only affects product quality, but also shortens the lifetime of MWFs. Two QS inhibiting agents, patulin and furanone C-30, both reduced biofilm formation in MWF when compared to untreated controls.

39Biofilms can promote bacteria survival in harsh environments. Conventional antibiotics and bactericides cannot penetrate the extracellular matrix of biofilms, resulting in decreased bacterial sensitivity, and therefore, biofilm-related pollution poses serious problems in many fields, including the environment, food, and human diseases. The formation of a biofilm is regulated by the QS system, and thus the use of QS inhibiting agents is a promising strategy to control biofilm formation, and it has been successfully applied in a number of fields.

40QS inhibiting agents control biofilm formation generally by targeting QS signaling molecules or their receptors, or downstream regulatory factors. They do not kill bacteria or inhibit the growth of bacteria, and instead they interfere with the expression of virulence factors and inhibit biofilm formation, which puts less pressure on bacterial survival and reduces their drug resistance. This is completely different from the mechanism of antibiotics killing bacteria.

41In recent years, many natural or synthetic QS inhibiting agents that effectively reduce biofilm formation have been exploited. However, there are still several problems to be overcome: (1) the mechanisms of some QS inhibiting agents in controlling biofilms are still unclear; (2) some known QS inhibiting agents are cytotoxic or unstable; (3) the anti-biofilm effect is not broad enough, only being effective against one or two bacterial species; (4) what are the best conditions for QS inhibiting agents in controlling biofilms? (5) whether QS inhibiting agents have an impact on beneficial bacteria in the environment. These problems all need to be overcome to develop more efficient, less toxic QS inhibiting agents that will provide great value in the future for biofilm prevention and treatment.

42JP and LZ provided the general concept and designed the manuscript and revised and approved the manuscript. LZ, YG, YZ, and XZ wrote the manuscript. LZ contributed to create the figure. All authors contributed to the article and approved the submitted version.

43The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.